What will disrupt members on January 1, 2027, and how do we sell into it?
Data through Through July 2026, covering plan years 2027-2028 · Updated July 17, 2026
curated
8 dated events point at January 1, 2027, and 6 of them are already final CMS actions: the second round of negotiated drug prices (semaglutide included), the GLP-1 Bridge, triple-weighted KED in the October 2026 star release, public prior-auth data, and new FIDE-SNP competition. The one big unknown, the size of the 2027 exit wave, resolves when non-renewal notices and ANOCs post in early October 2026, days before AEP 2027 opens.
8
Tracked disruption events, plan years 2027-2028
Through July 2026, covering plan years 2027-2028
6
Already final CMS actions
Through July 2026, covering plan years 2027-2028
8
Events hitting members on January 1, 2027
Through July 2026, covering plan years 2027-2028
6
Events that compound into plan year 2028
Through July 2026, covering plan years 2027-2028
The pipeline, in date order
| Window | Status | Event and mechanism | Who is disrupted |
|---|---|---|---|
| Announced July 2026; shapes 2027 formularies and bids | FINAL | Medicare GLP-1 Bridge expands GLP-1 access GLP-1 coverage differences become shoppable at AEP 2027. Plans that lean into Bridge coverage gain a concrete, high-salience benefit story for diabetes and cardio populations; plans that restrict it hand rivals a switch trigger. |
Diabetes and cardiometabolic members, C-SNP populations, and any member paying cash for GLP-1s today. |
| Ongoing; sanctions can land before or during AEP 2027 | WATCH | Star-integrity and prior-auth enforcement docket CMS has an active enforcement thread: AIPD warning letters to 23 plans over possible star-measure gaming, and a civil money penalty against Humana for prior-auth delays affecting roughly 84,000 members in FL and TX. Enforcement outcomes can reduce ratings or restrict marketing mid-cycle, instantly changing local competitive maps. |
Members of sanctioned contracts, who become contestable the moment a sanction or rating reduction is announced. |
| 14 contracts approved Feb 2026; scaling through 2027 | FINAL | New FIDE-SNP entrants scale in the Deep South Fourteen new FIDE-SNP contracts, concentrated in MS, AL, LA, and AR, bring first integrated options to the highest-density, lowest-coverage duals states. Because duals hold a recurring SEP, this competition disrupts incumbents every month, not just on January 1. |
Dual-eligible members in low-coverage Southern states, including members of non-integrated D-SNPs whose value story weakens against FIDE entrants. |
| Early October 2026 (non-renewal and ANOC mail) | EXPECTED | 2027 non-renewal and service-area reduction notices The annual exit cycle repeats: plans terminated for 2027 orphan their members effective January 1, 2027. The 2026 wave displaced 2.1M members and 62% of them actively shopped, so a 2027 wave of any size is contestable volume. The +2.48% final 2027 rate eases pressure, but carriers still in margin recovery decided their 2027 bids in June 2026 and may prune again. |
Members of any plan non-renewed for 2027; members crosswalked into higher-premium successors. |
| Finalized April 2026; visible in October 2026 ANOCs | FINAL | Final 2027 rate (+2.48%) reshapes benefit strategy unevenly The final 2027 payment update came in well above the near-flat Advance Notice, easing benefit-cut pressure. But relief lands unevenly: carriers that held benefits through the trough can now invest, while margin-recovery carriers may still trim. ANOC deltas in October 2026 are the member-visible result. |
Members of plans that cut benefits or raise premiums for 2027 despite the better rate; their ANOC is the switch trigger. |
| October 2026 (ratings display during AEP 2027) | FINAL | 2027 Star Ratings publish with KED at triple weight The October 2026 release is the rating shoppers see on Medicare.gov throughout AEP 2027, and the Kidney Health Evaluation measure carries a 3x weight for the first time. Carriers with weak or unreported KED performance face composite pressure exactly when it is most visible. |
Members of any contract whose displayed rating drops, especially across the 4.0-star bonus and marketing threshold. |
| January 1, 2027 (prices final; announced January 2025) | FINAL | 15 negotiated drug prices take effect, semaglutide included The second negotiation cycle applies maximum fair prices to 15 more high-spend drugs, headlined by the semaglutide family (Ozempic, Rybelsus, Wegovy). Plans reshuffle tiers and preferred products around the new prices, so members on these drugs see cost and formulary changes in their October 2026 ANOC. |
Part D and MA-PD members taking any of the 15 selected drugs; PDP members whose plans reprice around the change. |
| Effective January 2027; public data accrues through 2027 | FINAL | Prior-auth transparency reporting goes public From January 2027, MA plans must report prior-authorization denial rates, decision times, and appeal outcomes quarterly, posted publicly on Medicare.gov. Denial behavior becomes a shoppable metric for the first time. |
Members of high-denial plans, who gain an objective reason to switch once the data posts. |
Status: FINAL cites a published CMS action; EXPECTED marks a recurring statutory cycle not yet published for 2027; WATCH marks an open docket. Sources and dates per event are in the strategy table below.
The response: AEP 2027 play and 2028 setup, per event
| Event | AEP 2027 play (Oct 15 to Dec 7, 2026) | Plan year 2028 setup | Source |
|---|---|---|---|
| Medicare GLP-1 Bridge expands GLP-1 access | Lead with GLP-1 coverage in diabetes-heavy counties (cross-reference C-SNP share by state); make the coverage-vs-restriction contrast explicit in rep scripts and broker material. | GLP-1 adherence flows into diabetes-linked star measures over time, including the newly tripled KED weight, so 2027 coverage decisions become 2028 quality and marketing positions. | CMS GLP-1 Bridge announcement (Jul 2026) |
| Star-integrity and prior-auth enforcement docket | Put the enforcement docket on the weekly watch list; a sanction announced in an AEP window is the highest-urgency trigger in the taxonomy, and reps in affected counties should hear about it same-week. | Compliance posture compounds: carriers that exit this docket clean can sell trust in 2028; repeat offenders inherit a public paper trail. | CMS AIPD warning letters (Jan 2026); Humana CMP (Mar 2026) |
| New FIDE-SNP entrants scale in the Deep South | Deploy community partnerships in the affected states before the new entrants scale their ground game; the D-SNP deployment page ranks the uncovered-duals pools these contracts will contest. | Integration expectations keep rising; carriers with demonstrated FIDE capability enter 2028 bid season with a structural product advantage in duals-heavy markets. | CMS FIDE-SNP contract approvals (Feb 2026) |
| 2027 non-renewal and service-area reduction notices | Pre-build county capture kits now using the 2026 capture patterns; when notices post in October 2026, re-rank territories within days and re-run broker outreach in exited counties before rivals arrive. | Log which carriers pruned two cycles running; their remaining books carry switching momentum and their reps lose local credibility going into AEP 2028. | Annual CMS non-renewal process; 2026-cycle behavior from CMS crosswalk files (see AEP target markets) |
| Final 2027 rate (+2.48%) reshapes benefit strategy unevenly | Run ANOC-delta comparisons county by county as 2027 landscape data posts; target counties where a rival cut while your product held or improved. | The 2028 Advance Notice lands February 2027 and sets the next bid cycle's pressure; the carriers that cut twice in a row are the 2028 vulnerability list. | CMS 2027 Rate Announcement (Apr 2026) |
| 2027 Star Ratings publish with KED at triple weight | Refresh the carrier battlecards the week the ratings post; a rival slipping below 4.0 stars in October is a citable, dated fact for the whole selling window. | KED and CAHPS trajectories set the 2028 ratings; track measure-level erosion now to know next year's vulnerable rivals before they do. | CMS star methodology update (Mar 2026); annual October publication cycle |
| 15 negotiated drug prices take effect, semaglutide included | Target members on the negotiated-15 with drug-level cost comparisons at AEP; train reps on MFP talking points so the price story lands as plan value, not government backdrop. | The 2028 selection cycle expands negotiation further; build the drug-level comparison playbook once so each new cycle is a data refresh, not a rebuild. | HHS selection announcement (Jan 2025) and CMS proposed rule on MFP effectuation (Jun 2026) |
| Prior-auth transparency reporting goes public | Prepare the comparison framework during 2027 as quarterly data lands; use OEP 2027 conversations to test which PA facts move members. | The first full year of public PA data is the new battlecard column for AEP 2028; wire it into the disenrollment roadmap pipeline when the file lands. | CMS prior authorization transparency final rule (Feb 2026) |
The plays and setup notes are MedicareInsights editorial strategy, not CMS guidance. The pages that execute them: AEP target markets (exit wave), battlecards (stars, enforcement), D-SNP deployment (FIDE competition), and policy: what changed (the underlying CMS actions).
So what / Now what
AEP 2027 (October 15 to December 7, 2026) will be decided by events that are already dated. Most of the pipeline is final, not speculative: the negotiated drug prices, the GLP-1 expansion, the star methodology change, and the prior-auth transparency rule are published; only the size of the 2027 exit wave is still unknown until notices post in October 2026. Teams that build the response to each event before its date treat AEP as execution; teams that wait treat it as news. Everything here also compounds into plan year 2028: this cycle's KED scores, PA data, and FIDE positioning are next cycle's selling facts.
- Sales ops: put every dated window below on the AEP 2027 war-room calendar now, each with a named owner and a pre-built response (capture kit, talk track, or comparison sheet).
- The week of October 2026 is the collision point: star ratings, ANOCs, non-renewals, and landscape files all land within days. Staff the analytics refresh for that week in advance.
- Run the 2028 setup column as a standing backlog: KED trajectories, public PA data, and FIDE capability are 2028 differentiators that must be built during 2027.
- Treat expected and watch rows as scenarios, not facts, and re-check each against the CMS source before external use; this page re-dates as CMS publishes.
Provenance — 2027 disruption pipeline (plan years 2027-2028)
- Source file
- CMS newsroom, Federal Register, CMS rate and star publications (curated forward calendar)
- Vintage
- Through July 2026, covering plan years 2027-2028
- Last updated
- July 17, 2026
- Refresh cadence
- Reviewed monthly; re-dated as CMS publishes each cycle milestone
- Method
- Analyst-curated calendar of dated CMS actions and statutory milestones that can disrupt members effective January 1, 2027 or during plan year 2027, each mapped to a sales response for AEP 2027 (October 15 to December 7, 2026) and a setup note for plan year 2028. Events marked final cite a published CMS action; expected marks a recurring statutory cycle not yet published for 2027; watch marks an open docket.
- Known limitations
- Curated selection, not a complete feed. The AEP 2027 plays and 2028 setup notes are editorial strategy, not CMS guidance. Expected and watch items are forward-looking and may not occur as described.